De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6:e441.

Article  PubMed  PubMed Central  Google Scholar 

Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179–87.

Article  CAS  PubMed  Google Scholar 

Shah A, Andersson TM, Rachet B, Bjorkholm M, Lambert PC. Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study. Br J Haematol. 2013;162:509–16.

Article  PubMed  Google Scholar 

Märklin M, Hagelstein I, Koerner SP, Rothfelder K, Pfluegler MS, Schumacher A, et al. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia. J Immunother Cancer. 2019;7:143.

Article  PubMed  PubMed Central  Google Scholar 

Hofmann M, Grosse-Hovest L, Nubling T, Pyz E, Bamberg ML, Aulwurm S, et al. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia. Leukemia. 2012;26:1228–37.

Article  CAS  PubMed  Google Scholar 

Durben M, Schmiedel D, Hofmann M, Vogt F, Nübling T, Pyz E, et al. Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia. Mol Ther: J Am Soc Gene Ther. 2015;23:648–55.

Article  CAS  Google Scholar 

Beyar-Katz O, Gill S. Novel Approaches to Acute Myeloid Leukemia Immunotherapy. Clin Cancer Res. 2018;24:5502–15.

Article  CAS  PubMed  Google Scholar 

Chen Y, Wang J, Zhang F, Liu P. A perspective of immunotherapy for acute myeloid leukemia: current advances and challenges. Front Pharm. 2023;14:1151032.

Article  CAS  Google Scholar 

Maurer S, Zhong X, Prada BD, Mascarenhas J, de Andrade LF. The latest breakthroughs in immunotherapy for acute myeloid leukemia, with a special focus on NKG2D ligands. Int J Mol Sci. 2022;23:15907.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mehta NK, Pfluegler M, Meetze K, Li B, Sindel I, Vogt F, et al. A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL. J Immunother Cancer. 2022;10:e003882.

Article  PubMed  PubMed Central  Google Scholar 

Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 2020;10:506–25.

Article  CAS  PubMed  Google Scholar 

Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs. 2010;70:1445–76.

Article  CAS  PubMed  Google Scholar 

Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011;9:16–32.

Article  PubMed  Google Scholar 

Heitmann JS, Schlenk RF, Dorfel D, Kayser S, Dohner K, Heuser M, et al. Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease. J Hematol Oncol. 2023;16:96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47:115–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503–10.

Article  CAS  PubMed  Google Scholar 

Kellner C, Otte A, Cappuzzello E, Klausz K, Peipp M. Modulating cytotoxic effector functions by Fc engineering to improve cancer therapy. Transfus Med Hemother. 2017;44:327–36.

Article  PubMed  PubMed Central  Google Scholar 

Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA. 2006;103:4005–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chashchina A, Marklin M, Hinterleitner C, Salih HR, Heitmann JS, Klimovich B. DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis. Sci Rep. 2021;11:18012.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marconato M, Kauer J, Salih HR, Marklin M, Heitmann JS. Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia. Sci Rep. 2022;12:15856.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kauer J, Schwartz K, Tandler C, Hinterleitner C, Roerden M, Jung G, et al. CD105 (Endoglin) as negative prognostic factor in AML. Sci Rep. 2019;9:18337.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heitmann JS, Hagelstein I, Hinterleitner C, Roerden M, Jung G, Salih HR, et al. Identification of CD318 (CDCP1) as novel prognostic marker in AML. Ann Hematol. 2020;99:477–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ritz J. Immunologic targets in AML. Blood Cancer Discov. 2023;4:430–2.

Article  PubMed  Google Scholar 

Wang L, Zhang Q, Chen W, Shan B, Ding Y, Zhang G, et al. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PLoS ONE. 2013;8:e70689.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA. 2007;104:19458–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang L, Cao NN, Wang S, Man HW, Li PF, Shan BE. Roles of coinhibitory molecules B7-H3 and B7-H4 in esophageal squamous cell carcinoma. Tumour Biol. 2016;37:2961–71.

Article  CAS  PubMed  Google Scholar 

Hagelstein I, Engel M, Hinterleitner C, Manz T, Marklin M, Jung G, et al. B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma. Front Immunol. 2022;13:1002898.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hagelstein I, Lutz MS, Schmidt M, Heitmann JS, Malenke E, Zhou Y, et al. Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas. Front Immunol. 2021;12:653081.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zekri L, Lutz M, Prakash N, Manz T, Klimovich B, Mueller S, et al. An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers. Mol Ther. 2023;31:1033–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin MZ, Jin WL. The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020;5:166.

Article  PubMed  PubMed Central  Google Scholar 

Mu X, Chen C, Dong L, Kang Z, Sun Z, Chen X, et al. Immunotherapy in leukaemia. Acta Biochim Biophys Sin (Shanghai). 2023;55:974–87.

Article  CAS  PubMed  Google Scholar 

Hofmeyer KA, Ray A, Zang X. The contrasting role of B7-H3. Proc Natl Acad Sci USA. 2008;105:10277–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen L, Chen J, Xu B, Wang Q, Zhou W, Zhang G, et al. B7-H3 expression associates with tumor invasion and patient’s poor survival in human esophageal cancer. Am J Transl Res. 2015;7:2646–60.

CAS  PubMed  PubMed Central  Google Scholar 

Brustmann H, Igaz M, Eder C, Brunner A. Epithelial and tumor-associated endothelial expression of B7-H3 in cervical carcinoma: relation with CD8+ intraepithelial lymphocytes, FIGO stage, and phosphohistone H3 (PHH3) reactivity. Int J Gynecol Pathol. 2015;34:187–95.

Article  CAS  PubMed